Sfoglia per Autore
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease
2025 Riva, C; Minetto, P; Chies, M; Vernarecci, C; Colombo, N; Rosellini, S; Parodi, A; Tedone, E; Carminati, E; Nurra, C; Puglisi, F; Frello, M; Maio, E; Ferro, B; Zecchetti, G; Fugazza, G; Nozza, P; Cea, M; Lemoli, R; Guolo, F
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
2025 Lorusso, D; Colombo, N; Dubot, C; Cáceres, M; Hasegawa, K; Shapira-Frommer, R; Salman, P; Yañez, E; Gümüş, M; Olivera, M; Samouëlian, V; Castonguay, V; Arkhipov, A; Li, K; Toker, S; Tekin, C; Tewari, K; Monk, B
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer
2025 Randall, L; Xiang, Y; Matsumoto, T; Giannarelli, D; Milla, D; Lopez, K; Acevedo, A; Vizkeleti, J; Salani, R; Nogueira-Rodrigues, A; Mejia, F; Korach, J; Akilli, H; Lee, J; Saevets, V; Samouelian, V; Sehouli, J; Tharavichikul, E; Sukhin, V; Colombo, N; Chang, C; Cueva, J; Lalondrelle, S; Petru, E; Szamreta, E; Nguyen, A; Yamada, K; Li, K; Pignata, S; Lorusso, D
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
2025 Kim, Y; Nishio, S; Kim, S; Hasegawa, K; Dubot, C; Valeria Cáceres, M; Tewari, K; Lorusso, D; Lee, J; Liou, W; Li, K; Tekin, C; Colombo, N; Monk, B
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025
2025 Concin, N; Matias-Guiu, X; Cibula, D; Colombo, N; Creutzberg, C; Ledermann, J; Mirza, M; Vergote, I; Abu-Rustum, N; Bosse, T; Chargari, C; Espenel, S; Fagotti, A; Fotopoulou, C; Gatius, S; Gonzalez-Martin, A; Lax, S; Levy, B; Lorusso, D; Macchia, G; Marth, C; Morice, P; Oaknin, A; Raspollini, M; Schwameis, R; Sehouli, J; Sturdza, A; Taylor, A; Westermann, A; Wimberger, P; Planchamp, F; Nout, R
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
2025 Banerjee, S; Van Nieuwenhuysen, E; Aghajanian, C; D'Hondt, V; Monk, B; Clamp, A; Prendergast, E; Oaknin, A; Ring, K; Colombo, N; Holloway, R; Rodrigues, M; Chon, H; Gourley, C; Santin, A; Thaker, P; Gennigens, C; Newman, G; Salinas, E; Youssoufian, H; Moore, K; Lustgarten, S; O'Malley, D; Van Gorp, T; Grisham, R
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial
2025 Ledermann, J; Oza, A; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, J; Clamp, A; Scambia, G; Leary, A; Holloway, R; Gancedo, M; Fong, P; Goh, J; O'Malley, D; Armstrong, D; Banerjee, S; Garcia-Donas, J; Swisher, E; Lebreton, C; Konecny, G; Mcneish, I; Scott, C; Maloney, L; Goble, S; Lin, K; Coleman, R
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial
2025 Harano, K; Fossati, R; Pardo, B; Galli, F; Hudson, E; Antill, Y; Lee, C; Rabaglio, M; Heitz, F; Kolovetsiou-Kreiner, V; Lai, C; Biagioli, E; Manso, L; Nishio, S; Allan, K; Lee, Y; Uggeri, S; Redondo, A; Nakagawa, S; Au, E; Lombard, J; Gadducci, A; Takehara, K; Baldini, E; Palaia, I; Casanova, C; Ardizzoia, A; Bologna, A; Barretina-Ginesta, M; Colombo, N
Predictors of recurrence in early-stage cervical cancer without adjuvant treatment after radical surgery
2025 Caruso, G; Gaiano, M; De Vitis, L; Stefani, E; Rosanu, M; Ribero, L; Alessi, S; Petralia, G; Casarin, J; Gandini, S; Maggioni, A; Aletti, G; Zanagnolo, V; Colombo, N; Schivardi, G; Multinu, F
Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial
2025 Blons, H; Abdelli, J; Landman, S; Taly, V; Mulot, C; Laurent-Puig, P; You, B; Harter, P; Lorusso, D; Garcia-Garcia, Y; Polterauer, S; Hietanen, S; Colombo, N; Vergote, I; Kobayashi, H; De La Motte Rouge, T; Buderath, P; Cecere, S; Bataillon, G; Pujade-Lauraine, E; Ray-Coquard, I
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial
2025 Lorusso, D; Oaknin, A; Borges, G; Damian, F; Ottevanger, N; Van Gorp, T; Paiva, C; Kroep, J; Kim, Y; Kim, H; Lee, J; Denys, H; Lalisang, R; De Melo, A; Redondo, A; Reyners, A; Mora, P; Closset, C; Melief, C; Hooftman, L; Jamil, S; Boersma, L; Yoo, S; Seebach, F; Lowy, I; Fury, M; Mathias, M; Colombo, N
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2025 Valenza, C; Nicolò, E; Mongillo, M; Trapani, D; Katrini, J; Boldrini, L; Boscolo Bielo, L; Castellano, G; Guidi, L; Pellizzari, G; Villa, J; Derio, S; Lapresa, M; Gigli, F; Parma, G; Omodeo Salè, E; Derenzini, E; Curigliano, G; Colombo, N
Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer
2025 Caruso, G; Kumar, A; Langstraat, C; Mcgree, M; Fought, A; Harrington, S; Nasioudis, D; Aletti, G; Colombo, N; Giuntoli, R; Cliby, W
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
2025 Matulonis, U; Herrstedt, J; Oza, A; Mahner, S; Redondo, A; Berton, D; Berek, J; Haslund, C; Marme, F; Gonzalez-Martin, A; Becourt, S; Tinker, A; Ledermann, J; Benigno, B; Lindahl, G; Colombo, N; Malinowska, I; Liu, W; Bains, M; Monk, B; Mirza, M
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
2025 Bogani, G; Moore, K; Ray-Coquard, I; Lorusso, D; Matulonis, U; Ledermann, J; González-Martín, A; Kurtz, J; Pujade-Lauraine, E; Scambia, G; Caruso, G; Raspagliesi, F; Colombo, N; Monk, B
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
2025 Oaknin, A; Monk, B; de Melo, A; Kim, H; Kim, Y; Lisyanskaya, A; Samouëlian, V; Lorusso, D; Damian, F; Chang, C; Gotovkin, E; Takahashi, S; Ramone, D; Maćkowiak-Matejczyk, B; Polastro, L; Alia, E; Colombo, N; Makarova, Y; Goh, J; Hasegawa, K; Mora, P; Pikiel, J; Srivastav, R; Rischin, D; Rubio, M; Perez, J; Yoo, S; Gao, B; Jamil, S; Seebach, F; Lowy, I; Mathias, M; Fury, M; Tewari, K
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer
2025 Grisham, R; Monk, B; Van Nieuwenhuysen, E; Moore, K; Fabbro, M; O'Malley, D; Oaknin, A; Thaker, P; Oza, A; Colombo, N; Gershenson, D; Aghajanian, C; Choi, C; Lee, Y; Mirza, M; Coleman, R; Cobb, L; Harter, P; Lustgarten, S; Youssoufian, H; Banerjee, S
Systems epigenetic approach towards non-invasive breast cancer detection
2025 Herzog, C; Theeuwes, B; Jones, A; Evans, I; Bjørge, L; Zikan, M; Cibula, D; Harbeck, N; Colombo, N; Pashayan, N; Widschwendter, M
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status: Clinical Studies
2025 Pignata, S; Oza, A; Hall, G; Pardo, B; Madry, R; Cibula, D; Klat, J; Montes, A; Glasspool, R; Colombo, N; Pete, I; Herrero Ibanez, A; Romeo, M; Ilieva, R; Timcheva, C; Di Maio, M; Bashir, Z; Taylor, R; Barnicle, A; Clamp, A
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation
2025 Konstantinopoulos, P; Kim, J; Freyer, G; Lee, J; Gaba, L; Grisham, R; Colombo, N; Wu, X; Sehouli, J; Cruz, F; Cibula, D; Monk, B; Nyvang, G; Friedlander, M; Lorusso, D; Van Nieuwenhuysen, E; Malik, R; Glasspool, R; Marth, C; Leary, A; Cortés-Salgado, A; Zamagni, C; Marmé, F; Sufliarsky, J; Hinson, P; Zuradelli, M; Wang, C; Su, F; Paule, I; Miller, M; Matulonis, U; González-Martín, A
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile